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Introduction
leading to new disease insight and potential new approaches to treatment. It has been shown matched European-ancestry heavy smokers from the extreme high and extreme low % 126 predicted FEV1 subsets defined for the UK BiLEVE study (Figure 1, Table 1 ). DNA samples for 127 these 5000 individuals were prepared by UK Biobank and provided back to the University of 133 paralogue ratio test (PRT) 134 CCL3L1 copy number was determined using a triplex paralogue ratio test (PRT) assay as used 135 previously [24, 26] . Briefly, PRT is a comparative PCR method that amplifies a test and 136 reference locus using the same pair of primers, followed by capillary electrophoresis and 137 quantification of the two products [32, 36] . The triplex assay produced three independent 138 estimates of copy number per test, of which the average was taken as a representative copy 139 number value. The three values were consistent in 95% of samples, however, for 5% of samples 140 the value from the LTR61A PRT assay was significantly lower than the other two PRT values, and 141 an average of the two consistent PRTs was taken in these 5% of samples. For each typing 142 experiment, 4 positive controls of known copy number were also included, as previously [26, 143 37]. The copy number values clustered about integer copy numbers, and a Gaussian mixture 144 model was fitted to allow assignment of individuals to an integer copy number call using 151 Matched RNAseq data that is publically available for the 1000 genomes samples were grouped 152 based on CCL3L1 copy number and analysed for their differential expression using Cufflinks Association analysis 189 We tested for association of CCL3L1 copy number and CCR5d32 genotype separately with lung 190 function extremes (as a binary trait) using logistic regression with pack-years of smoking and 191 the first ten principal components (obtained previously using full genome-wide SNP genotyping 192 data to adjust for fine-scale population structure as covariates [33] . For CCR5d32, a genotypic 193 genetic model was assumed for the primary analysis. We then fitted a full linear regression 194 model that included CCR5d32 genotype (genotypic mode), CCL3L1 copy number, pack years, 10 195 principal components and a term for the interaction of CCR5d32 and CCL3L1.
CCL3L1 copy number estimation in UK Biobank and 1000 Genomes Project samples using the

Gene Expression levels in 1000 genomes project lymphoblastoid cell lines
Results
200
Using CNVrd2, we typed CCL3L1 copy number from whole genome sequence alignments for 201 2502 individuals from the 1000 Genomes project (Figure 2a ). The data were grouped into large 202 superpopulations, as defined by the 1000 Genomes Project [44] , and our analysis confirmed 203 previous observations that Europeans have the lowest CCL3L1 diploid copy number, ranging 204 between 0 and 5 with a mean copy number of 1.97, and sub-Saharan Africans have the highest 205 diploid copy number, ranging between 1 and 9 with a mean of 4.19, which is more than twice 206 as high as Europeans (Table 2) [24, 25] .
208
For 144 individuals from the CEU (n=96) and YRI (n=48) populations of the 1000 Genomes 209 project, we also determined CCL3L1 copy number using the PRT approach (Figure 2b ). There 210 was strong concordance between results, with discrete clusters of raw data, representing 211 individual integer copy numbers, formed, particularly at low copy number. For the range seen 212 in Europeans (copy numbers 0 to 5), there are seven clear discrepancies which gives an joint 213 error rate of 5%.
215
To confirm previous studies that reported an association between CCL3L1 copy number and 216 CCL3L1 mRNA levels, we compared the 1000 Genomes Project CCL3L1 copy numbers with 217 transcript levels of CCL3L1 and its non-copy number variable paralogue CCL3, as generated by 218 RNAseq of the corresponding B-lymphoblastoid cell lines (Figures 3a, 3b ). Comparison with 219 transcript level estimates using RNAseq data showed a clear positive correlation between 220 CCL3L1 copy number and expression level (figure 3b, r 2 =0.25, p<2x10 -16 ). We used the specific 221 sequence changes between CCL3L and CCL3 to distinguish transcripts from either gene, and 
226
We confirmed an increase of one to two orders of magnitude for CCL3 transcript levels 227 compared to CCL3L1 transcript levels in B-lymphoblast cells. Following normalization of the 228 CCL3L1 expression levels to CCL3 expression levels, we show that CCL3L1 transcript levels are 229 closely correlated with gene copy number (Figure 3c , r 2 =0.5, p<2x10 -16 ).
population [24] , and with our estimation from the 1000 Genomes project samples. The two 243 copy genotype was the most frequent with a frequency of 0.563. The CCL3L1 zero copy null 244 genotype is uncommon, with a frequency of 2.5% in the UK. 4993 of the 5000 UK Biobank 245 samples were genotyped for CCR5d32 by imputation with the genotypes for 474 individuals 246 validated using direct PCR analysis. There was no evidence that the genotype frequencies 247 departed from Hardy-Weinberg equilibrium (chi-squared test, p=0.35) and the observed 248 CCR5d32 deletion allele frequency was 0.11, consistent with previous estimates [13] .
250
A total of 4975 UK Biobank individuals had both CCL3L1 copy number and CCR5d32 genotypes 251 measured (2486 high and 2489 low FEV1, Table 4 ). There was no evidence of an association 252 between CCL3L1 copy number and CCR5d32 genotype (chi-squared test p=0.803).
254
We fitted a full model with both CCR5 genotypes (genotypic model) and CCL3L1 copy number 255 and an interaction term as described above. This was undertaken in order to identify whether 256 particular combinations of CCL3L1 copy number and CCR5d32 genotype were differentially 257 associated with lung function. Pack years of smoking and 10 principal components were 258 included as covariates. No associations were significant (Table 5) .
Discussion
264
Our study provides robust large-scale confirmation of a gene dosage effect of CCL3L1 copy 265 number on CCL3L1 mRNA levels, and also emphasises the strong dependence of CCL3L1:CCL3 266 mRNA ratio on copy number, with CCL3L1 copy number accounting for 50% of total variation.
267
Although it is clear that CCL3L1 is expressed at much lower levels than CCL3, the MIP1alpha 268 isoform encoded by CCL3L1 (LD78beta) has a much stronger affinity to the CCR5 receptor than 269 MIP1alpha isoform CCL3 (LD78alpha). It therefore seems likely that the CCL3L1 copy number 270 variation mediates a biological effect in vivo. It should be noted that the expression data are from 271 transformed B-lymphoblastoid cell lines, but a gene dosage effect is consistent with a study using 272 fresh monocytes from 55 different individuals stimulated with bacterial lipopolysccharide [28] .
274
Our analysis provides evidence that there is no effect of either CCL3L1 copy number or CCR5d32 275 genotype, or any combinations of genotypes at the two loci, on lung function. This suggests that, 276 although the Mip1alpha-CCR5 signaling axis can be disrupted by artificial CCR5 antagonists, there 277 is no evidence that this axis has a functional effect on lung function and that development of new 278 drugs to target this axis, or repurposing of existing drugs, might be of little or no therapeutic 279 benefit in treating COPD.
281
We analysed approximately 5000 individuals. Whilst this represents a large sample size for 282 labour-intensive PRT assays, it is a modest sample size in comparison with those employed in 283 GWAS. That said, power was boosted by selecting from the extremes of the lung function 284 distribution in the very large (n~500K) UK Biobank.
286
We reported PRT error rates of 2.5% for the 144 1000 Genomes Project samples and between 287 0% and 4.75% for the 4981 UK Biobank participants. A previous study using this PRT approach 288 estimated an error rate of less than 0.1% [24] , which suggests that much of the joint error rate 289 for the PRT and sequence read depth could be due to errors in the sequence read depth 290 approach.
292
The exact boundaries of the CCL3L1 CNV have yet to be determined with precision but it is known 
